Literature DB >> 22089527

Fallopian tube correlates of ovarian serous borderline tumors.

Anna R Laury1, Gang Ning, Charles M Quick, Jonathan Bijron, Mana M Parast, Rebeca A Betensky, Sara O Vargas, Frank D McKeon, Wa Xian, Marisa R Nucci, Christopher P Crum.   

Abstract

Ovarian serous borderline tumors (SBTs) are presumed to originate in the ovarian cortex or peritoneal surface. The pathogenetic role of the fallopian tube (FT) is unclear; however, recently, secretory cell outgrowths (SCOUTs) lacking PAX2 expression were described in benign FTs. This study addressed (1) the differentiation characteristics of SBTs and (2) the frequency of SCOUTs lacking PAX2 expression in the FTs of patients with SBTs and compared (3) SCOUT morphology and (4) PAX2 expression with SBTs. SBTs and FT epithelium shared both ciliated (p73) and secretory (HMFG2) differentiation. PAX2-null SCOUT frequency in FT cross-sections from patients with SBTs was 0.28 (110 of 398) versus 0.112 in benign hysterectomies and nearly 0 in pediatric and postpartum sterilization specimens (P = < 0.001). When adjusted for age, the differences narrowed but remained significant (P = 0.010). SCOUTs were heterogeneous, some displaying ciliated differentiation and papillary architecture. Two cases of discrete multifocal papillary SCOUTs in the FTs were associated with SBTs. All SBTs had heterogeneous PAX2 staining with areas of PAX2 loss. This study shows for the first time that PAX2-null SCOUTs are more common in the oviducts of women with SBTs and that loss of PAX2 expression occurs in most SBTs. These discoveries link both morphologic and functional gene (PAX2) alterations in the oviduct to SBTs, similar to that reported in high-grade serous carcinoma. Further study is warranted to clarify the relationship of the oviduct to serous neoplasia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089527      PMCID: PMC3219906          DOI: 10.1097/PAS.0b013e318233b0f7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  25 in total

1.  Epithelial hyperplasia of the fallopian tube.

Authors:  G Dallenbach-Hellweg
Journal:  Int J Gynecol Pathol       Date:  1990       Impact factor: 2.762

2.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Authors:  Y Lee; A Miron; R Drapkin; M R Nucci; F Medeiros; A Saleemuddin; J Garber; C Birch; H Mou; R W Gordon; D W Cramer; F D McKeon; C P Crum
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996

3.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

4.  A survey of epithelial inclusions in the ovarian cortex of 470 patients.

Authors:  R M Mulligan
Journal:  J Surg Oncol       Date:  1976       Impact factor: 3.454

5.  Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.

Authors:  Rebecca T Marquez; Keith A Baggerly; Andrea P Patterson; Jinsong Liu; Russell Broaddus; Michael Frumovitz; Edward N Atkinson; David I Smith; Lynn Hartmann; David Fishman; Andrew Berchuck; Regina Whitaker; David M Gershenson; Gordon B Mills; Robert C Bast; Karen H Lu
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

Review 6.  Pathology of ovarian cancer precursors.

Authors:  R E Scully
Journal:  J Cell Biochem Suppl       Date:  1995

7.  Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants.

Authors:  N L Sieben; G M J M Roemen; J Oosting; G J Fleuren; M van Engeland; J Prat
Journal:  J Pathol       Date:  2006-12       Impact factor: 7.996

8.  Induction of a differentiated ciliated cell phenotype in primary cultures of Fallopian tube epithelium.

Authors:  M T Comer; H J Leese; J Southgate
Journal:  Hum Reprod       Date:  1998-11       Impact factor: 6.918

9.  Differential expression of the glycosylated forms of MUC1 during lung development.

Authors:  J Sakurai; N Hattori; M Nakajima; T Moriya; T Suzuki; A Yokoyama; N Kohno
Journal:  Eur J Histochem       Date:  2007 Apr-Jun       Impact factor: 3.188

10.  Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?

Authors:  Guo-Xia Tong; Luis Chiriboga; Diane Hamele-Bena; Alain C Borczuk
Journal:  Mod Pathol       Date:  2007-05-25       Impact factor: 7.842

View more
  19 in total

1.  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Authors:  Marcin P Iwanicki; Hsing-Yu Chen; Claudia Iavarone; Ioannis K Zervantonakis; Taru Muranen; Marián Novak; Tan A Ince; Ronny Drapkin; Joan S Brugge
Journal:  JCI Insight       Date:  2016-07-07

2.  PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.

Authors:  Angela Russo; Austin A Czarnecki; Matthew Dean; Dimple A Modi; Daniel D Lantvit; Laura Hardy; Seth Baligod; David A Davis; Jian-Jun Wei; Joanna E Burdette
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

3.  Tubal origin of ovarian low-grade serous carcinoma.

Authors:  Chenglu Chen; Jie Li; Guang Yao; Setsuko K Chambers; Wenxin Zheng
Journal:  Am J Clin Exp Obstet Gynecol       Date:  2013-12-15

Review 4.  The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

Review 5.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

6.  The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium.

Authors:  Gang Ning; Jonathan G Bijron; Yusuke Yamamoto; Xia Wang; Brooke E Howitt; Michael Herfs; Eric Yang; Yue Hong; Maxence Cornille; Lingyan Wu; Suchanan Hanamornroongruang; Frank D McKeon; Christopher P Crum; Wa Xian
Journal:  J Pathol       Date:  2014-09-30       Impact factor: 7.996

7.  Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.

Authors:  Robertson Mackenzie; Aline Talhouk; Sima Eshragh; Sherman Lau; Daphne Cheung; Christine Chow; Nhu Le; Linda S Cook; Nafisa Wilkinson; Jacqueline McDermott; Naveena Singh; Friedrich Kommoss; Jacobus Pfisterer; David G Huntsman; Martin Köbel; Stefan Kommoss; C Blake Gilks; Michael S Anglesio
Journal:  Am J Surg Pathol       Date:  2015-11       Impact factor: 6.394

8.  Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis.

Authors:  Robert J Kurman; Russell Vang; Jette Junge; Charlotte Gerd Hannibal; Susanne K Kjaer; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

Review 9.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.

Authors:  Jaime Prat
Journal:  Virchows Arch       Date:  2012-02-10       Impact factor: 4.064

Review 10.  Coming into focus: the nonovarian origins of ovarian cancer.

Authors:  L Dubeau; R Drapkin
Journal:  Ann Oncol       Date:  2013-11       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.